The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma
Open accessAbstract
EZ Inhibition: Missense mutations in the core constituents of the genome packaging material, chromatin, have been implicated in several of human cancers. Nucleosomes are made up of histones, and a mutation of lysine 27 (K27) to methionine in the N-terminal tail of histone variants H3.3 and H3.1 has been identified in various pediatric gliomas. Lewis et al. (p. 857 , published online 28 March; see the Perspective by Morgan and Shilatifard ) show that the polycomb enzyme complex, which can epigenetically modify K27 by addition of a methyl group—and which is often a silencing signal—is itself potently inhibited by replacement of the H3.3/3.1 K27 by methionine. The inhibition of the EZH2 subunit causes an overall reduction of K27 methylation. Methionine mutants of other methylated lysine residues in histone H3 cause similar reductions in methylation levels of the cognate lysine, altering the epigenetic profiles of such cancer cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, tumor cells with the K27M mutation exhibit low levels of H3K27me3 and aberrant gene silencing (4,(7)(8)(9).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“act in a dominant manner to deplete H3K27 methylation by inhibiting PRC2 methyltransferase activity [5, 6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Additional histone H3 lysine-to-methionine mutants possess dominant gain-of-function activities [6]”
From Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling (2014) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“We and others previously showed that K-to-M oncohistones transform the histone H3 proteins into potent inhibitors of specific lysine methyltransferase enzymes (4-7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies showed that the K27M mutation found in pediatric glioma is sufficient to transform histone H3 into a potent inhibitor of enzymatic activity of PRC2 (4, 5, 7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“we previously showed that H3K9M peptides are capable of inhibiting activity of SUV39H1 and G9a, two H3K9-directed methyltransferases, in vitro (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Previously, we found that only long, unbranched hydrophobic side chains containing methionine (M) and isoleucine (I) at lysine 27 (K27M and K27I) were capable of inhibiting PRC2 in vitro and decreasing H3K27me3 when expressed ectopically in cultured cells (7).”
From S -adenosyl methionine is necessary for inhibition of the methyltransferase G9a by the lysine 9 to methionine mutation on histone H3 (2016) · cites this paper as [7]
In the citing paper
“Despite reports supporting a higher affinity of PRC2 for H3K27M as compared with wild-type H3 108-110 , H3K27M was often inversely correlated with PRC2 occupancy, challenging the idea that H3K27M sequesters PRC2 on chromatin 111,112 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [112]
In the citing paper
“Expression of the histone mutant is accompanied by a reduction in the levels of Polycomb Repressive Complex 2 (PRC2) mediated H3K27 trimethylation (H3K27me3) and this is purported to be a driving event of DIPG oncogenesis4,5.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Interestingly upon loss of H3K27me3 these nucleosomes acquire H3K27ac resulting in the formation of H3K27M-K27ac heterotypic nucleosomes4 (Figure 1D and Supplementary Fig. 5B–C).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“As shown by our group and others, H3K27M expression is associated with increased levels of H3K27ac4,5 (Fig. 1D).”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Although still functionally active, PRC2 catalytic property toward H3K27M containing nucleosomes is strongly inhibited4.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Collectively, these results strongly indicate that H3K27M in DIPG cells does not appear to recruit or sequester EZH2 (or in general PRC2), as suggested by other studies4,6,7.”
From Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas (2017) · cites this paper as [4]
In the citing paper
“Attempts to model H3.3K27M-driven HGG formation in vivo via genetic recombination in neural progenitor/stem cells (NPCs) in the postnatal brain failed to demonstrate tumor-driving activity”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
In the citing paper
“H3.3K27M has been shown to have gain-of-function activity inhibiting the Polycomb Repressive Complex 2 (PRC2) (Bender et al., 2013; Lewis et al., 2013), which in turn leads to a global reduction in H3K27me3 levels in primary tumors and tumor-derived primary cells.”
From H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas (2017) · cites this paper as Lewis et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project (2012) · Nature Genetics · doi:10.1038/ng.1102 · Cited by 1,724
Taverna, S. D., Li, H., Ruthenburg, A. J., Allis, C. D., & Patel, D. J. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1338 · Cited by 1,476
Self-citationRole of the polycomb protein EED in the propagation of repressive histone marks
Margueron, R., Justin, N., Ohno, K., Sharpe, M. L., Son, J., Drury, W. J., Voigt, P., Martin, S. R., Taylor, W. R., Marco, V. D., et al. (2009) · Nature · doi:10.1038/nature08398 · Cited by 1,281
Khuong-Quang, D.-A., Buczkowicz, P., Rakopoulos, P., Liu, X.-Y., Fontebasso, A. M., Bouffet, E., Bartels, U., Albrecht, S., Schwartzentruber, J., Letourneau, L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0998-0 · Cited by 1,028
Roles of the EZH2 histone methyltransferase in cancer epigenetics
Simon, J. A., & Lange, C. A. (2008) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2008.07.010 · Cited by 880
Sneeringer, C. J., Scott, M. P., Kuntz, K. W., Knutson, S. K., Pollock, R. M., Richon, V. M., & Copeland, R. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012525107 · Cited by 719
Yap, D., Chu, J., Berg, T., Schapira, M., Cheng, S., Moradian, A., Morin, R. D., Mungall, A. J. J., Meissner, B., Boyle, M., et al. (2010) · Blood · doi:10.1182/blood-2010-11-321208 · Cited by 633
A Novel Mammalian Flavin-dependent Histone Demethylase
Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, C., & Mattevi, A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.003087 · Cited by 274
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 999
Chromatin regulatory mechanisms and therapeutic opportunities in cancer
Valencia, A. M., & Kadoch, C. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0258-1 · Cited by 213
Catarino, R. R., & Stark, A. (2018) · Genes & Development · doi:10.1101/gad.310367.117 · Cited by 215
PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism
Jain, S. U., Do, T. J., Lund, P. J., Rashoff, A. Q., Diehl, K. L., Cieslik, M. P., Bajic, A., Juretic, N., Deshmukh, S., Venneti, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09981-6 · Cited by 225
Self-citationChung, C., Sweha, S. R., Pratt, D. W., Tamrazi, B., Panwalkar, P., Banda, A., Bayliss, J. M., Hawes, D., Yang, F., Lee, H., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.008 · Cited by 204
Histone H3 lysine-to-methionine mutants as a paradigm to study chromatin signaling
Herz, H.-M., Morgan, M., Gao, X., Jackson, J., Rickels, R., Swanson, S. K., Florens, L., Washburn, M. P., Eissenberg, J. C., & Shilatifard, A. (2014) · Science · doi:10.1126/science.1255104 · Cited by 199
H3F3A K27M mutations in thalamic gliomas from young adult patients
Aihara, K., Mukasa, A., Gotoh, K., Saito, K., Nagae, G., Tsuji, S., Tatsuno, K., Yamamoto, S., Takayanagi, S., Narita, Y., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not144 · Cited by 202
Chi, A. S., Tarapore, R. S., Hall, M. D., Shonka, N., Gardner, S. L., Umemura, Y., Sumrall, A. L., Khatib, Z. A., Mueller, S., Kline, C., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03271-3 · Cited by 199
Hennika, T., Hu, G., Olaciregui, N. G., Barton, K. L., Ehteda, A., Chitranjan, A., Chang, C., Gifford, A. J., Tsoli, M., Ziegler, D. S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169485 · Cited by 191
Self-citationPanditharatna, E., Kilburn, L. B., Aboian, M., Kambhampati, M., Gordish‐Dressman, H., Magge, S. N., Gupta, N. M., Myseros, J. S., Hwang, E. I., Kline, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1345 · Cited by 197
ATRX and DAXX: Mechanisms and MutationsPreprint
Dyer, M. A., Qadeer, Z. A., Valle‐García, D., & Bernstein, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026567 · Cited by 208
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Liu, F., Hon, G. C., Villa, G. R., Turner, K. M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A. Y., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.002 · Cited by 194
Bayliss, J. M., Mukherjee, P., Lü, C., Jain, S. U., Chung, C., Martínez, D., Sabari, B. R., Margol, A., Panwalkar, P., Parolia, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aah6904 · Cited by 197
Self-citationMultiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma
Stafford, J. M., Lee, C., Voigt, P., Descostes, N., Saldaña-Meyer, R., Yu, J.-R., LeRoy, G., Oksuz, O., Chapman, J. R., Suarez, F., et al. (2018) · Science Advances · doi:10.1126/sciadv.aau5935 · Cited by 197
DNA repair mechanisms and their clinical impact in glioblastoma
Erasimus, H., Gobin, M., Niclou, S. P., & Dyck, E. V. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.05.005 · Cited by 203
The Mcm2-Ctf4-Polα Axis Facilitates Parental Histone H3-H4 Transfer to Lagging Strands
Gan, H., Serra‐Cardona, A., Hua, X., Zhou, H., Labib, K. P. M., Yu, C., & Zhang, Z. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.09.001 · Cited by 192
Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis
Chen, C. C. L., Deshmukh, S., Jessa, S., Hadjadj, D., Lisi, V., Andrade, A. F., Faury, D., Jawhar, W., Dali, R., Suzuki, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.012 · Cited by 199
Self-citationAnastas, J. N., Zee, B. M., Kalin, J. H., Kim, M., Guo, R., Alexandrescu, S., Blanco, M. A., Giera, S., Gillespie, S. M., Das, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.005 · Cited by 197
Driver mutations of cancer epigenomes
Roy, D. M., Walsh, L. A., & Chan, T. A.-T. (2014) · Protein & Cell · doi:10.1007/s13238-014-0031-6 · Cited by 188
Molecular architecture of polycomb repressive complexes
Chittock, E. C., Latwiel, S., Miller, T. C. R., & Müller, C. W. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160173 · Cited by 208
EpiProfile 2.0: A Computational Platform for Processing Epi-Proteomics Mass Spectrometry Data
Yuan, Z., Sidoli, S., Marchione, D. M., Simithy, J., Janssen, K. A., Szurgot, M. R., & Garcia, B. A. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00133 · Cited by 188
Self-citationNagaraja, S., Quezada, M. A., Gillespie, S. M., Arzt, M., Lennon, J., Woo, P. J., Hovestadt, V., Kambhampati, M., Filbin, M. G., Suvà, M. L., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.030 · Cited by 190
Histone variants: key players of chromatin
SÜT, B. B., & Schneider, R. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-1862-4 · Cited by 208
Guo, Y., Zhao, S., & Wang, G. G. (2021) · Trends in Genetics · doi:10.1016/j.tig.2020.12.006 · Cited by 199
An Interactive Database for the Assessment of Histone Antibody Specificity
Rothbart, S. B., Dickson, B. M., Raab, J. R., Grzybowski, A. T., Krajewski, K., Guo, A. H., Shanle, E. K., Josefowicz, S. Z., Fuchs, S. M., Allis, C. D., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.022 · Cited by 187
Self-citationLin, C.-J., Koh, F. M., Wong, P., Conti, M., & Ramalho‐Santos, M. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.022 · Cited by 179
Pan-cancer patterns of DNA methylation
Witte, T., Plass, C., & Gerhäuser, C. (2014) · Genome Medicine · doi:10.1186/s13073-014-0066-6 · Cited by 182
Huang, T., Piunti, A., Lulla, R. R., Qi, J., Horbinski, C., Tomita, T., James, C. D., Shilatifard, A., & Saratsis, A. M. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0436-6 · Cited by 180
Greater Than the Sum of Parts: Complexity of the Dynamic Epigenome
Soshnev, A. A., Josefowicz, S. Z., & Allis, C. D. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.004 · Cited by 181
Self-citationRai, T. S., Cole, J. J., Nelson, D. M., Dikovskaya, D., Faller, W. J., Vizioli, M. G., Hewitt, R. N., Anannya, O., McBryan, T., Manoharan, I., et al. (2014) · Genes & Development · doi:10.1101/gad.247528.114 · Cited by 162
The Epigenetic Hallmarks of Cancer
Esteller, M., Dawson, M. A., Kadoch, C., Rassool, F. V., Jones, P. A., & Baylin, S. B. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0296 · Cited by 202
Cancer Stem Cell Plasticity – A Deadly Deal
Thankamony, A. P., Saxena, K., Murali, R., Jolly, M. K., & Nair, R. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00079 · Cited by 178
Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition
Hogg, S. J., Motorna, O., Cluse, L. A., Johanson, T. M., Coughlan, H. D., Raviram, R., Myers, R. M., Costacurta, M., Todorovski, I., Pijpers, L., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.015 · Cited by 170
Interrogating the Function of Metazoan Histones using Engineered Gene Clusters
McKay, D. J., Klusza, S., Penke, T. J. R., Meers, M. P., Curry, K. P., McDaniel, S. L., Malek, P. Y., Cooper, S. W., Tatomer, D. C., Lieb, J. D., et al. (2015) · Developmental Cell · doi:10.1016/j.devcel.2014.12.025 · Cited by 173
Histone variants: emerging players in cancer biology
Vardabasso, C., Hasson, D., Ratnakumar, K., Chung, C., Duarte, L. F., & Bernstein, E. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1343-z · Cited by 178
Venneti, S., Kawakibi, A. R., Ji, S., Waszak, S. M., Sweha, S. R., Mota, M., Pun, M. J., Deogharkar, A., Chung, C., Tarapore, R. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0131 · Cited by 167
Barton, K. L., Misuraca, K. L., Cordero, F. J., Dobrikova, E. Y., Min, H. D., Gromeier, M., Kirsch, D. G., & Becher, O. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077639 · Cited by 163
Self-citationDiagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast‐rich mimics
Presneau, N., Baumhoer, D., Behjati, S., Pillay, N., Tarpey, P. S., Campbell, P. J., Jundt, G., Hamoudi, R., Wedge, D. C., Loo, P. V., et al. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.13 · Cited by 165
Harnessing the potential of epigenetic therapy to target solid tumors
Ahuja, N., Easwaran, H., & Baylin, S. B. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69736 · Cited by 165
Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG
Cordero, F. J., Huang, Z., Grenier, C., He, X., Hu, G., McLendon, R. E., Murphy, S. K., Hashizume, R., & Becher, O. J. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0389 · Cited by 157
Self-citationHistone editing elucidates the functional roles of H3K27 methylation and acetylation in mammals
Sankar, A., Mohammad, F., Sundaramurthy, A. K., Wang, H., Lerdrup, M., Tatar, T., & Helin, K. (2022) · Nature Genetics · doi:10.1038/s41588-022-01091-2 · Cited by 157
Hass, R., von der Ohe, J., & Ungefroren, H. (2020) · Cancers · doi:10.3390/cancers12123716 · Cited by 154
Jang, Y., Broun, A., Wang, C., Park, Y.-K., Zhuang, L., Lee, J., Froimchuk, E., Liu, C., & Ge, K. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky982 · Cited by 150
Venneti, S., Santi, M., Felicella, M. M., Yarilin, D. A., Phillips, J. J., Sullivan, L. M., Martínez, D., Perry, A., Lewis, P. W., Thompson, C. B., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1338-3 · Cited by 153
Self-citationMeeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 155
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential
Beltran, H. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0536 · Cited by 148
Mechanisms of Polycomb group protein function in cancer
Parreno, V., Martinez, A., & Cavalli, G. (2022) · Cell Research · doi:10.1038/s41422-021-00606-6 · Cited by 158
Jessa, S., Mohammadnia, A., Harutyunyan, A. S., Hulswit, M., Varadharajan, S., Lakkis, H., Kabir, N., Bashardanesh, Z., Hébert, S., Faury, D., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01205-w · Cited by 150
Self-citationBenítez, J. A., Ma, J., D’Antonio, M., Boyer, A. D., Camargo, M. F., Zanca, C., Kelly, S., Khodadadi‐Jamayran, A., Jameson, N. M., Andersen, M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15223 · Cited by 147
H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2
Jain, S. U., Rashoff, A. Q., Krabbenhoft, S. D., Hoelper, D., Do, T. J., Gibson, T. J., Lundgren, S. M., Bondra, E. R., Deshmukh, S., Harutyunyan, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.09.028 · Cited by 150
Self-citationHübner, J.-M., Müller, T., Papageorgiou, D. N., Mauermann, M., Krijgsveld, J., Russell, R. B., Ellison, D. W., Pfister, S. M., Pajtler, K. W., & Kool, M. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz058 · Cited by 155
Interplay between chromatin marks in development and disease
Janssen, S. M., & Lorincz, M. C. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00416-x · Cited by 147
Diverse Epigenetic Mechanisms of Human Disease
Brookes, E., & Shi, Y. (2014) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092518 · Cited by 145
Spatially controlled construction of assembloids using bioprinting
Roth, J. G., Brunel, L. G., Huang, M. S., Liu, Y., Cai, B., Sinha, S., Yang, F., Pașca, S. P., Shin, S., & Heilshorn, S. C. (2023) · Nature Communications · doi:10.1038/s41467-023-40006-5 · Cited by 149
Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer
Zeng, Z., Fu, M., Hu, Y., Wei, Y., Wei, X., & Luo, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01877-w · Cited by 155
PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease
Kadoch, C., Copeland, R. A., & Keilhack, H. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01191 · Cited by 146
Toledo, R. A., Qin, Y., Cheng, Z.-M., Gao, Q., Iwata, S., Silva, G. M., Prasad, M. L., Ocal, I. T., Rao, S. N., D, N. A. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1841 · Cited by 146
Diverse involvement of EZH2 in cancer epigenetics.
Völkel, P., Dupret, B., Bourhis, X. L., & Angrand, P. (2015) · PubMed · Cited by 142
Methylation across the central dogma in health and diseases: new therapeutic strategies
Liu, R., Zhao, E., Yu, H., Yuan, C., Abbas, M. N., & Cui, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01528-y · Cited by 155
Xie, J., Wooten, M., Tran, V., Chen, B., Pozmanter, C., Simbolon, C., Betzig, E., & Chen, X. (2015) · Cell · doi:10.1016/j.cell.2015.10.002 · Cited by 139
Emerging roles for Polycomb proteins in cancer
Pasini, D., & Di Croce, L. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.03.013 · Cited by 133
Ezponda, T., Dupéré-Richer, D., Will, C., Small, E. C., Varghese, N., Patel, T., Nabet, B., Popovic, R., Oyer, J. A., Bulic, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.078 · Cited by 141
Precision oncology in the age of integrative genomics
Kumar‐Sinha, C., & Chinnaiyan, A. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4017 · Cited by 138
Béchet, D., Gielen, G. H., Korshunov, A., Pfister, S. M., Rousso, C., Faury, D., Fiset, P., Benlimame, N., Lewis, P. W., Lü, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1337-4 · Cited by 139
Self-citationYan, J., Li, B., Lin, B., Lee, P. T., Chung, T., Tan, J. M.-L., Bi, C., Lee, X. T., Selvarajan, V., Ng, S., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690701 · Cited by 137
Chudnovsky, Y., Kim, D., Zheng, S., Whyte, W. A., Bansal, M., Bray, M.-A., Gopal, S., Theisen, M. A., Bilodeau, S., Thiru, P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2013.12.032 · Cited by 136
Molecular basis for oncohistone H3 recognition by SETD2 methyltransferasePreprint
Yang, S., Zheng, X., Lü, C., Li, G., Allis, C. D., & Li, H. (2016) · Genes & Development · doi:10.1101/gad.284323.116 · Cited by 141
Self-citationHistone H3.3 Mutations: A Variant Path to Cancer
Yuen, B. T. K., & Knoepfler, P. S. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.015 · Cited by 139
Amary, F. M., Berisha, F., Mozela, R., Gibbons, R., Guttridge, A., O’Donnell, P., Baumhoer, D., Tirabosco, R., & Flanagan, A. M. (2016) · Histopathology · doi:10.1111/his.12945 · Cited by 136
Genome-wide redistribution of H3K27me3 is linked to genotoxic stress and defective growth
Basenko, E. Y., Sasaki, T., Ji, L., Prybol, C. J., Burckhardt, R. M., Schmitz, R. J., & Lewis, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1511377112 · Cited by 135
Diffuse Intrinsic Pontine Glioma: New Pathophysiological Insights and Emerging Therapeutic Targets
Johung, T., & Monje, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160509123229 · Cited by 131
Allosteric Activation Dictates PRC2 Activity Independent of Its Recruitment to Chromatin
Lee, C., Yu, J.-R., Kumar, S., Jin, Y., LeRoy, G., Bhanu, N. V., Kaneko, S., Garcia, B. A., Hamilton, A. D., & Reinberg, D. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.020 · Cited by 140
Self-citationCastel, D., Philippe, C., Kergrohen, T., Sill, M., Merlevede, J., Barret, E., Puget, S., Sainte‐Rose, C., Kramm, C. M., Jones, C., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0614-1 · Cited by 139
Pagès, M., Beccaria, K., Boddaert, N., Saffroy, R., Besnard, A., Castel, D., Fina, F., Barets, D., Barret, E., Lacroix, L., et al. (2016) · Brain Pathology · doi:10.1111/bpa.12473 · Cited by 131
Shaping the cellular landscape with Set2/SETD2 methylation
McDaniel, S. L., & Strahl, B. D. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2517-x · Cited by 130
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia
McNeer, N. A., Philip, J., Geiger, H. M., Ries, R. E., Lavallée, V., Walsh, M. F., Shah, M. J., Arora, K. S., Emde, A., Robine, N., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0402-3 · Cited by 130
Diffuse Intrinsic Pontine Glioma: From Diagnosis to Next-Generation Clinical Trials
Vitanza, N. A., & Monje, M. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0577-y · Cited by 134
Cohen, K. J., Jabado, N., & Grill, J. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox021 · Cited by 143
ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis
Hoeman, C. M., Cordero, F. J., Hu, G., Misuraca, K., Romero, M. M., Cardona, H. J., Nazarian, J., Hashizume, R., McLendon, R. E., Yu, P. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08823-9 · Cited by 133
Self-citationDzobo, K., Senthebane, D. A., Ganz, C., Thomford, N. E., Wonkam, A., & Dandara, C. (2020) · Cells · doi:10.3390/cells9081896 · Cited by 132
Jamieson, K., Wiles, E. T., McNaught, K. J., Sidoli, S., Leggett, N. A., Shao, Y., Garcia, B. A., & Selker, E. U. (2015) · Genome Research · doi:10.1101/gr.194555.115 · Cited by 138
Self-citationDiffuse intrinsic pontine glioma: a reassessment
Robison, N. J., & Kieran, M. W. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1448-8 · Cited by 131
Histone H3 Mutations: An Updated View of Their Role in Chromatin Deregulation and Cancer
Lowe, B. R., Maxham, L., Hamey, J. J., Wilkins, M. R., & Partridge, J. F. (2019) · Cancers · doi:10.3390/cancers11050660 · Cited by 133
New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M
Karsy, M. J., Guan, J., Cohen, A. L., Jensen, R. L., & Colman, H. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0722-5 · Cited by 128
Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma
Buczkowicz, P., & Hawkins, C. E. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00147 · Cited by 128
DAXX in cancer: phenomena, processes, mechanisms and regulation
Mahmud, I., & Liao, D. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz634 · Cited by 122
Cancer epigenetics: Past, present and future
Lee, J. E., & Kim, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.025 · Cited by 132
Silveira, A. B., Kasper, L. H., Fan, Y., Jin, H., Wu, G., Shaw, T. I., Zhu, X., Larson, J. D., Easton, J. B., Shao, Y., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01975-4 · Cited by 129
Feng, J., Hao, S., Pan, C., Wang, Y., Wu, Z., Zhang, J., Yan, H., Zhang, L., & Wan, H. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.07.002 · Cited by 121
Pediatric Brain Tumor Genetics: What Radiologists Need to Know
AlRayahi, J., Zápotocký, M., Ramaswamy, V., Hanagandi, P. B., Branson, H. M., Mubarak, W. M., Raybaud, C., & Laughlin, S. (2018) · Radiographics · doi:10.1148/rg.2018180109 · Cited by 125
Bhan, A., Hussain, I., Ansari, K. I., Bobzean, S. A. M., Perrotti, L. I., & Mandal, S. S. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.07.025 · Cited by 123
Hörmanseder, E., Simeone, A., Allen, G. E., Bradshaw, C. R., Figlmüller, M., Gurdon, J. B., & Jullien, J. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.03.003 · Cited by 120
Role of Radiation Therapy in the Management of Diffuse Intrinsic Pontine Glioma: A Systematic Review
Gallitto, M., Lazarev, S., Wasserman, I., Stafford, J. M., Wolden, S. L., Terezakis, S. A., Bindra, R. S., & Bakst, R. L. (2019) · Advances in Radiation Oncology · doi:10.1016/j.adro.2019.03.009 · Cited by 120
H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model
Haag, D., Mack, N. L., da Silva, P. B. G., Statz, B., Clark, J., Tanabe, K., Sharma, T., Jäger, N., Jones, D., Kawauchi, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.01.005 · Cited by 127
Epigenetic Targeting of Glioblastoma
Romani, M., Pistillo, M. P., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00448 · Cited by 119
Nuclear deformation guides chromatin reorganization in cardiac development and disease
Seelbinder, B., Ghosh, S., Schneider, S. E., Scott, A. K., Berman, A. G., Goergen, C. J., Margulies, K. B., Bedi, K. C., Casas, E., Swearingen, A. R., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00823-9 · Cited by 115
Brown, Z. Z., Müller, M. M., Jain, S. U., Allis, C. D., Lewis, P. W., & Muir, T. W. (2014) · Journal of the American Chemical Society · doi:10.1021/ja5060934 · Cited by 111
Self-citationFilipescu, D., Müller, S., & Almouzni, G. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100913-013311 · Cited by 121
Saratsis, A. M., Kambhampati, M., Snyder, K. A., Yadavilli, S., Devaney, J. M., Harmon, B. T., Hall, J., Raabe, E. H., An, P., Weingart, M., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1218-2 · Cited by 120
K27M-mutant histone-3 as a novel target for glioma immunotherapy
Ochs, K., Ott, M., Bunse, T., Sahm, F., Bunse, L., Deumelandt, K., Sonner, J. K., Keil, M., von Deimling, A., Wick, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328340 · Cited by 120
Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications
Wang, W. T., Qin, J., Voruganti, S., Nag, S. A., Zhou, J., & Zhang, R. (2015) · Medicinal Research Reviews · doi:10.1002/med.21358 · Cited by 118
Metadata
- Authors
- Lewis, P. W., Müller, M. M., Koletsky, M. S., Cordero, F., Lin, S., Banaszynski, L. A., Garcia, B. A., Muir, T. W., Becher, O. J., & Allis, C. D.
- Affiliations
- Rockefeller University (US)
- Princeton University (US)
- Duke University (US)
- University of Pennsylvania (US)
- Corresponding author
- Allis, C. David
- ORCID
- Venue
- Science
- Published
- 2013-05-17
- Volume
- 340
- Issue
- 6134
- Pages
- 857-861
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3951439
- OpenAlex
- W1995105508
- Cited by
- 1,345
- References
- 14
- Citations by year
- 2026: 73 · 2025: 82 · 2024: 103 · 2023: 106 · 2022: 103 · 2021: 118 · 2020: 146 · 2019: 112 · 2018: 84 · 2017: 102 · 2016: 90 · 2015: 95 · 2014: 87 · 2013: 40
- FWCI
- 51.21
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Portal (King's College London) (submittedVersion)
- Funders
- National Institutes of Health (DP2OD007447)
- National Institute of Mental Health (P50MH096890)
- National Institute of General Medical Sciences (GM040922, R01GM107047, R01GM040922)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pediatric glioblastoma, diffuse intrinsic pontine glioma, H3K27M mutation, histone H3.3, H3K27me3, polycomb repressive complex 2, EZH2, histone methylation, gain-of-function mutations, epigenetic regulation
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Animals, Brain Neoplasms, Child, Glioblastoma, Histones, Humans, Lysine, Methionine, Methylation, Transgenes, Amino Acid Substitution, Mutation, Missense, Epigenesis, Genetic, Mice, HEK293 Cells, Polycomb Repressive Complex 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
